Advertisement

Topics

NeoImmuneTech, Inc. Company Profile

22:07 EST 18th February 2019 | BioPortfolio

NeoImmuneTech (NIT), a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, Hyleukin-7, in the U.S. and EU. Based in Rockville, Maryland, NIT has the core competency of global clinical and business development with a strong scientific focus and a broad network of global leading R&D organizations. NIT is currently conducting Phase 1b/2a clinical trials of Hyleukin-7, aiming at developing not only the first-in-class treatment of lymphopenia but also a breakthrough cancer immunotherapy. www.neoimmunetech.com


News Articles [5 Associated News Articles listed on BioPortfolio]

NeoImmuneTech Announces Initiation of Clinical Trial for HyLeukin-7 Treatment in Combination ...

Read more...

NeoImmuneTech Announces Initiation of Clinical Trial for HyLeukin-7 Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients

NeoImmuneTech, Inc., an immunotherapy drug development company focused on advanced cancer treatments, today announced the U.S. Food and Drug Administration (FDA) approved i...

NeoImmuneTech Strengthens Senior Management with the Appointment of NgocDiep Le, M.D., Ph.D., as Chief Medical Officer

NeoImmuneTech, Inc., an immunotherapy drug development company focused on advanced cancer treatments, today announced the appointment of NgocDiep (‘Diep’) Le, M.D., Ph....

NeoImmuneTech Receives Authorization to Proceed from the FDA for IND Application to Evaluate Hyleukin-7 in Combination with a PD-L1 Inhibitor in Advanced High-Risk Skin Cancers

NeoImmuneTech, Inc., an immunotherapy drug development company focused on advanced cancer treatments, and Genexine, today announced that the U.S. Food and Drug Administrati...

NeoImmuneTech Presents Hyleukin-7 and Universal CAR-T Combination Therapy Preclinical Data at ASH Annual Meeting

-- Studies in B cell and T cell lymphoma models suggest Hyleukin-7 can significantly enhance and prolong CAR-T activity -- NeoImmuneTech, Inc., an immunotherapy drug de...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

NeoImmuneTech

NeoImmuneTech, a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, HyLeukin-7, in the US and EU. Base...

NeoImmuneTech, Inc.

NeoImmuneTech (NIT), a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, Hyleukin-7, in the U.S. and ...

More Information about "NeoImmuneTech, Inc." on BioPortfolio

We have published hundreds of NeoImmuneTech, Inc. news stories on BioPortfolio along with dozens of NeoImmuneTech, Inc. Clinical Trials and PubMed Articles about NeoImmuneTech, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NeoImmuneTech, Inc. Companies in our database. You can also find out about relevant NeoImmuneTech, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record